• J-M Classe, E Cerato, C Boursier, J Dauplat, C Pomel, R Villet, J Cuisenier, G Lorimier, J-F Rodier, P Mathevet, G Houvenaeghel, J Leveque, and F Lécuru.
• Département de chirurgie oncologique, centre René-Gauducheau-ICO, boulevard Jean-Monod, Nantes-Saint-Herblain, France. jm-classe@nantes.fnclcc.fr
• J Gynecol Obstet Biol Reprod (Paris). 2011 May 1; 40 (3): 201-4.

AbstractThe standard management for advanced-stage epithelial ovarian cancer is optimum cytoreductive surgery followed by platinum based chemotherapy. However, retroperitoneal lymph node resection remains controversial. The multiple directions of the lymph drainage pathway in ovarian cancer have been recognized. The incidence and pattern of lymph node involvement depends on the extent of the disease and the histological type. Several published cohorts suggest the survival benefit of pelvic and para-aortic lymphadenectomy. A recent large randomized trial have demonstrated the potential benefit for surgical removal of bulky lymph nodes in term of progression-free survival but failed to show any overall survival benefit because of a critical methodology. Further randomised trials are needed to balance risks and benefits of systematic lymphadenectomy in advanced-stage disease. CARACO is a French ongoing trial, built to bring a reply to this important question. A huge effort for inclusion of the patients, and involving new teams, are mandatory.Copyright © 2011 Elsevier Masson SAS. All rights reserved.

14 keywords...

hide…